Effect of VEGF165 and the VEGF aptamer pegaptanib (Macugen®) on the protein composition of tight junctions in microvascular endothelial cells of the retina;Wirkung von VEGF165 und dem VEGF-aptamer pegaptanib (Macugen®) auf die zusammensetzung der tight junctions mikrovaskulärer endothelzellen aus der retina

Klinische Monatsblatter fur Augenheilkunde

Volumn 225, Issue 10, 2008, Pages 863-867

  Deissler, Heidrun L ^a   Lang, G E ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Diabetic retinopathy; Pegaptanib; Retinal microvascular endothelial cells; VEGF; VEGF inhibitors

Indexed keywords

CLAUDIN 5; OCCLUDIN; PEGAPTANIB; PROTEIN ZO1; VASCULOTROPIN 165; APTAMER; UNCLASSIFIED DRUG; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CELL IMMORTALIZATION; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; IMMUNOFLUORESCENCE TEST; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETINA CELL; TIGHT JUNCTION; ANIMAL; CATTLE; CELL CULTURE; CORNEA ENDOTHELIUM; DRUG ANTAGONISM; METABOLISM; MICROCIRCULATION; PHYSIOLOGY; VASCULARIZATION;

ANIMALS; APTAMERS, NUCLEOTIDE; CATTLE; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, CORNEAL; MICROCIRCULATION; TIGHT JUNCTIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56149102814     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027767     Document Type: Article

References (33)

1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487
2. Antonetti DA, Barber AJ, Hollinger LA et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occludens 1. J Biol Chem 1999; 274: 23463-23467
3. Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost 2006; 95: 36-42
4. Behzadian MA, Windsor LJ, Ghaly N et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J 2003; 17: 752-754
5. Boulton M, Foreman D, Williams G et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561-568
6. Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-455
7. Caldwell RB, Bartoli M, Behzadian MA et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005; 6: 511-524
8. Deissler H, Deissler H, Lang GK et al. Generation and characterization of iBREC: novel hTERT-immortalized bovine retinal endothelial cells. Int J Mol Med 2005; 16: 65-70
9. Deissler H, Deissler H, Lang GK et al. TGFβ induces transdifferentiation of iBREC to αSMA-expressing cells. Int J Mol Med 2006; 18: 577-582
10. Deissler H, Kuhn EM, Lang GE et al. Tetraspanin CD 9 is involved in the migration of retinal microvascular endothelial cells. Int J Mol Med 2007; 20: 643-652
11. Deissler H, Deissler H, Lang S et al. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis®) in microvascular retinal endothelial cells. Br J Ophthalmol 2008; 92: 839-843
12. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611
13. Ferrara N, Damico L, Shams N et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-870
14. Harhaj NS, Felinski EA, Wolpert EB et al. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability. Invest Ophthalmol Vis Sci 2006; 47: 5106-5115
15. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006; 12: 5018-5022
16. Lowe J, Araujo J, Yang J et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007; 85: 425-430
17. Lutty GA, Mathews MK, Merges C et al. Adenosine stimulates canine retinal microvascular endothelial cell migration and tube formation. Curr Eye Res 1998; 17: 594-607
18. Malik RA, Li C, Aziz W et al. Elevated plasma CD 105 and vitreous VEGF levels in diabetic retinopathy. J Cell Mol Med 2005; 9: 692-697
19. Pan Q, Chathery Y, Wu Y et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 2007; 282: 24049-24056
20. Peters S, Julien S, Heiduschka P et al. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007; 91: 827-831
21. Qaum T, Xu Q, Joussen AM et al. VEGF-initialed blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42: 2408-2413
22. Raja TT, Grammas P. VEGF and VEGF receptor levels in retinal and brain-derived endlthelial cells. Bioch Biophys Res Commun 2002; 293: 710-713
23. Sakakibara A, Furuse M, Saitou M et al. Possible involvement of phosphorylation of occludin in tight junction formation. J Cell Biol 1997; 137: 1393-1401
24. Spitzer MS, Wallenfels-Thilo B, Sierra A et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006; 90: 1316-1321
25. Spitzer MS, Yoeruek E, Sierra A et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefe's Arch Clin Exp Ophthalmol 2007; 245: 1837-1842
26. Suzuma K, Takagi H, Otani A et al. Increased expression of KDR/Flk-1 (REGFR-2) in murine model of ischemia-induced retinal neovascularization. Microvasc Res 1998; 56: 183-191
27. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001; 2: 285-293
28. Vinores SA. Technology evaluation: pegaptanib, Eyetech/Pfizer. Curr Opin Mol Ther 2003; 5: 673-679
29. Watanabe D, Suzuma K, Suzuma I et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005; 139: 476-481
30. Witmer AN, Blaauwgeers HG, Weich HA et al. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF induced retinopathy in monkey. Invest Ophthalmol Vis Sci 2002; 43: 849-857
31. Wong V. Phosphorylation of occludin correlates with occludin localization and function at the tight junction. Am J Physiol 1997; 273: C1859-C1867
32. Wu LW, Mayo LD, Dunbar JD et al. Utilization of distinct signaling pathways by receptor for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 2000; 275: 5096-5103
33. Xia P, Aiello LP, Ishii H et al. Characterization of vascular endothelial growth factor's effect on the activation of Protein Kinase C, its isoforms and endothelial cell growth. J Clin Invest 1996; 98: 2018-2026